Terms: = Head and neck cancer AND XPO1, DKFZp686B1823, 7514, ENSG00000082898, O14980, CRM1 AND Treatment
7 results:
1. Molecular Modeling and In Vitro Evaluation of Piplartine Analogs against Oral Squamous Cell Carcinoma.
Silva RHN; Machado TQ; da Fonseca ACC; Tejera E; Perez-Castillo Y; Robbs BK; de Sousa DP
Molecules; 2023 Feb; 28(4):. PubMed ID: 36838660
[TBL] [Abstract] [Full Text] [Related]
2. Overview of Ocular Side Effects of Selinexor.
Al-Zubidi N; Gombos DS; Hong DS; Subbiah V; Fu S; Ahnert JR; Piha-Paul SA; Tsimberidou AM; Karp DD; Bernstam FM; Naing A
Oncologist; 2021 Jul; 26(7):619-623. PubMed ID: 33728727
[TBL] [Abstract] [Full Text] [Related]
3. Targeting xpo1 and PAK4 in 8505C Anaplastic Thyroid cancer Cells: Putative Implications for Overcoming Lenvatinib Therapy Resistance.
Khan HY; Ge J; Nagasaka M; Aboukameel A; Mpilla G; Muqbil I; Szlaczky M; Chaker M; Baloglu E; Landesman Y; Mohammad RM; Azmi AS; Sukari A
Int J Mol Sci; 2019 Dec; 21(1):. PubMed ID: 31905765
[TBL] [Abstract] [Full Text] [Related]
4. Selinexor (KPT-330) has antitumor activity against anaplastic thyroid carcinoma in vitro and in vivo and enhances sensitivity to doxorubicin.
Garg M; Kanojia D; Mayakonda A; Ganesan TS; Sadhanandhan B; Suresh S; S S; Nagare RP; Said JW; Doan NB; Ding LW; Baloglu E; Shacham S; Kauffman M; Koeffler HP
Sci Rep; 2017 Aug; 7(1):9749. PubMed ID: 28852098
[TBL] [Abstract] [Full Text] [Related]
5. Elevated expression of the nuclear export protein, crm1 (exportin 1), associates with human oesophageal squamous cell carcinoma.
van der Watt PJ; Zemanay W; Govender D; Hendricks DT; Parker MI; Leaner VD
Oncol Rep; 2014 Aug; 32(2):730-8. PubMed ID: 24898882
[TBL] [Abstract] [Full Text] [Related]
6. Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.
Tanaka Y; Yoshida K; Osada S; Yamaguchi K; Takahashi T
Anticancer Res; 2011 Dec; 31(12):4589-97. PubMed ID: 22199335
[TBL] [Abstract] [Full Text] [Related]
7. HuR is exported to the cytoplasm in oral cancer cells in a different manner from that of normal cells.
Hasegawa H; Kakuguchi W; Kuroshima T; Kitamura T; Tanaka S; Kitagawa Y; Totsuka Y; Shindoh M; Higashino F
Br J Cancer; 2009 Jun; 100(12):1943-8. PubMed ID: 19513080
[TBL] [Abstract] [Full Text] [Related]
